Drug delivery treatment device
View Patent ↗Disclosed are devices and methods for treatment of eye disease. The suprachoroidal space is used as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.
1. A method of delivering drug into the eye, comprising:
implanting an elongate member in an eye by inserting the elongate member through the cornea and through the anterior chamber, wherein the elongate member comprises a elongate member having a tubular first end, a second end, and an internal lumen with a first opening at the first end and a second opening adjacent the second end, and wherein the elongate member is implanted in the eye such that the first end is in the anterior chamber, the second end is positioned in communication with a suprachoroidal space of the eye, and at least a portion of the elongate member between the first end and the second end is positioned between the sclera and a ciliary body of the eye, the elongate member adapted to deliver a drug into the eye;
placing a treatment medium onto an outer surface of the eye;
permitting the treatment medium to flow into an anterior chamber of the eye; and
causing the treatment medium to flow into the internal lumen of the elongate member such that the treatment medium flows along the internal lumen of the elongate member into the suprachoroidal space.
2. A method as in claim 1 , wherein the treatment medium flows into the anterior chamber via tear film.
3. A method as in claim 1 , wherein the treatment medium flows into the anterior chamber via a punctal plug.
4. A method as in claim 1 , wherein the treatment medium mixes with aqueous humor as the treatment medium flows into the anterior chamber.
5. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the second end is positioned in an anterior portion of the eye.
6. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the second end is positioned between a sclera and a choroid of the eye.
7. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the second end is positioned between a sclera and a ciliary body of the eye.
8. A method as in claim 1 , wherein placing a treatment medium onto an outer surface of the eye comprises placing a drop of treatment medium onto an outer surface of the eye.
9. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the elongate member does not traverse the retina.
10. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the elongate member is positioned adjacent a scleral spur of the eye.
11. A method as in claim 1 , wherein the elongate member is implanted in the eye such that no portion of the elongate member between the first end and the second end is positioned inside the sclera.